Earnings summaries and quarterly performance for Erasca.
Executive leadership at Erasca.
Board of directors at Erasca.
Research analysts covering Erasca.
Recent press releases and 8-K filings for ERAS.
Erasca Closes Upsized Public Offering
ERAS
New Projects/Investments
- Erasca, Inc. (Nasdaq: ERAS) has closed its previously announced upsized public offering, selling a total of 25,875,000 shares of its common stock.
- The shares were sold at a price of $10.00 per share, generating approximately $258.8 million in gross proceeds for the company.
- Erasca intends to use the net proceeds to fund the research and development of its product candidates and other development programs, as well as for working capital and other general corporate purposes.
Jan 23, 2026, 9:01 PM
Erasca Announces Pricing of Upsized Public Offering
ERAS
New Projects/Investments
- Erasca, Inc. announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share.
- The offering is expected to generate gross proceeds of $225.0 million for Erasca, with underwriters having a 30-day option to purchase up to an additional 3,375,000 shares.
- The company intends to use the net proceeds to fund research and development of its product candidates and other development programs, as well as for working capital and general corporate purposes.
Jan 22, 2026, 1:54 AM
Erasca Announces Proposed Public Offering of Common Stock
ERAS
- Erasca, Inc. intends to offer and sell $150.0 million of its common stock in a proposed underwritten public offering.
- The company also plans to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock.
- The net proceeds from the offering are intended to fund research and development of product candidates and other development programs, as well as for working capital and general corporate purposes.
Jan 20, 2026, 9:01 PM
Erasca provides pipeline and financial update at JPMorgan Healthcare Conference
ERAS
New Projects/Investments
Guidance Update
- Erasca reported $362 million in cash in its Q3 earnings, providing a cash runway into the second half of 2028.
- The company's lead pan-RAS program, ERAS-15, has shown ongoing confirmed and unconfirmed partial responses in multiple patients at a low dose of eight milligrams QD in the AURORAS-1 trial, with a favorable safety profile and no dose-limiting toxicity.
- Top-line safety, tolerability, PK, and initial efficacy data for ERAS-15 are planned for the first half of 2026, and phase one monotherapy data for the pan-KRAS program, ERAS-4001, are expected in the second half of 2026.
- Both ERAS-15 and ERAS-4001 have strong IP exclusivity expected until 2043 and beyond.
Jan 13, 2026, 9:30 PM
Erasca Updates on Clinical Progress for ERAS-15 and ERAS-4001 at JPMorgan Healthcare Conference
ERAS
New Projects/Investments
Guidance Update
- Erasca reported $362 million in cash from its Q3 earnings, providing a cash runway into the second half of 2028.
- The company's lead pan-RAS program, ERAS-15, demonstrated ongoing confirmed and unconfirmed partial responses in multiple patients at a low dose of eight milligrams QD in the AURORAS-1 clinical trial, alongside a favorable safety and tolerability profile.
- Top-line safety, tolerability, PK, and initial efficacy data for ERAS-15 are anticipated in the first half of 2026.
- Erasca's pan-KRAS program, ERAS-4001, is currently enrolling the BOREALIS-1 trial, with phase one monotherapy data expected in the second half of 2026.
- Preclinical data for ERAS-15 showed comparable anti-tumor activity to a competitor's molecule (RMC-6236) at one-tenth of the dose.
Jan 13, 2026, 9:30 PM
Erasca Provides Updates on RAS-Targeting Pipeline and Financial Position
ERAS
New Projects/Investments
Guidance Update
- Erasca is focused on the RAS-MAP kinase pathway with two lead programs: ERAS-15, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS program.
- The company reported $362 million in cash in its Q3 earnings, providing a cash runway into the second half of 2028.
- Early clinical data for ERAS-15 from the AURORAS-1 trial shows ongoing confirmed and unconfirmed partial responses in multiple patients at a low dose of eight milligrams QD, with a favorable safety profile and linear PK. Preclinical data indicated ERAS-15 achieved comparable anti-tumor activity to RMC-6236 at one-tenth of the dose.
- Key upcoming milestones include Phase 1 monotherapy data for ERAS-15 in the first half of 2026 and for ERAS-4001 in the second half of 2026.
Jan 13, 2026, 9:30 PM
Erasca, Inc. Announces Clinical Progress and 2026-2027 Milestones
ERAS
New Projects/Investments
Product Launch
Guidance Update
- Erasca, Inc. (ERAS) announced clinical progress for its RAS-targeting franchise and 2026-2027 milestones on January 12, 2026.
- The AURORAS-1 Phase 1 trial for ERAS-0015 is advancing faster than anticipated, with initial monotherapy data expected in H1 2026.
- ERAS-0015 has shown ongoing confirmed and unconfirmed responses in multiple patients at a low dose of 8 mg QD, along with favorable safety and tolerability.
- Initial Phase 1 monotherapy data for ERAS-4001 in the BOREALIS-1 trial is anticipated in H2 2026.
Jan 12, 2026, 1:02 PM
Erasca Secures Patent Protection, Updates on Clinical Trials, and Financials
ERAS
Earnings
New Projects/Investments
Guidance Update
- Erasca, Inc. secured U.S. patent protection through 2043 for ERAS-0015, its potential best-in-class pan-RAS molecular glue.
- The company reported $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing a cash runway into the second half of 2028.
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 is expected in 2026.
- Erasca reported a net loss of $30.6 million for the third quarter ended September 30, 2025.
Dec 11, 2025, 3:17 PM
Erasca Provides Update on RAS-MAPK Pathway Oncology Programs and Financial Outlook
ERAS
New Projects/Investments
Guidance Update
- Erasca is an oncology company focused on eradicating RAS-driven cancers with two key programs: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor.
- Preclinically, ERAS-0015 demonstrates potential differentiation from Revolution Medicines' 6236, including 8- to 20-fold better binding to cyclophilin A and 4- to 5x greater in vitro potency.
- The company plans to disclose clinical data for both ERAS-0015 and ERAS-4001 in calendar year 2026, which will include safety, PK, and initial signs of activity from dozens of patients.
- Erasca ended the last quarter with $362 million in cash, providing a runway to the second half of 2028 to aggressively advance its programs, including multiple dose expansions and the initiation of Phase 3 trials.
Dec 3, 2025, 3:25 PM
Erasca Provides Update on Oncology Pipeline and 2026 Data Expectations
ERAS
New Projects/Investments
Guidance Update
- Erasca is advancing two oncology programs targeting the RAS-MAPK pathway: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor.
- Preclinically, ERAS-0015 demonstrates advantages over Revolution Medicines' 6236 compound, including 8- to 20-fold better binding to cyclophilin A and 4- to 5x greater in vitro potency.
- The company expects to disclose clinical data for both ERAS-0015 and ERAS-4001 in calendar year 2026, which will include safety, PK, and initial signs of activity from dozens of patients.
- Erasca reported a cash balance of $362 million at the end of the last quarter, providing a financial runway into the second half of 2028 to aggressively advance its programs.
Dec 3, 2025, 3:25 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more